In his weekly clinical update Dr. Griffin discusses prevalence and clinical outcomes of respiratory syncytial virus versus influenza virus in adults hospitalized with acute respiratory Illness, reconsideration of antinucleocapsid IgG antibody as a marker of SARS-CoV-2 infection postvaccination for mild COVID-19 patients, assessment of COVID-19 as the underlying cause of death among children and young people aged 0 to 19 years in the US, information for persons who are immunocompromised regarding prevention and treatment of SARS-CoV-2 Infection in the context of currently circulating Omicron sublineages, association of culturable-virus detection and household transmission of SARS-CoV-2, effectiveness of bivalent boosters against severe Omicron infection, Covid vaccines and playing the long game, efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalized with COVID-19, and severe fatigue and persistent symptoms at three months following SARS-CoV-2 Infections during the pre-Delta, Delta, and Omicron time periods.
In COVID-19 clinical update #86, Dr. Griffin discusses virologic features of infection in children, antibody tests should not be used to asses level of protection, test-to-stay programs in schools, FDA authorizes Moderna boosters, results of TOGETHER trial for fluvoxamine, statins and 28 day mortality, and cognitive function in patients.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Jolene Ramsey, Ph.D.